Table 5 Cumulative incidence of medium-term adverse events.

From: Correlation between toxicity and dosimetric parameters for adjuvant intensity modulated radiation therapy of breast cancer: a prospective study

 

Cumulative incidence [95% CI] of grade ≥ 2 adverse events after IMRT

At 13 months*

At 26 months*

Esophageal adverse events

–

–

Skin adverse events

1.1% [0.4–3.5]

1.7% [0.6–4.5]

Fibrosis, total mastectomy

4.5% [1.9–10.5]

7.0% [2.9–16.4]

Fibrosis, partial mastectomy

5.2% [2.6–10.2]

7.3% [3.5–15.1]

Scar fibrosis, total mastectomy

5.5% [2.5–11.9]

5.5% [2.5–11.9]

Scar fibrosis, partial mastectomy

5.7% [3.0–10.6]

7.8% [3.9–15.6]

  1. *The cumulative incidences are quoted at 13 and 26 months (rather than 12 and 24 months) so as not to underestimate the values, since the annual check-ups often took place slightly later than 12 and 24 months. Skin adverse events were defined as radiodermatitis, ulceration-necrosis, telangiectasia, atrophy, hyperpigmentation or hypopigmentation. With regard to surgical bed fibrosis, only fibrosis absent or of a higher grade on inclusion were considered.
Back to article page